Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. - Wikidata - wikimedia - TriplyDB

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

http://www.wikidata.org/entity/Q36182604

about

Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease Seeking a mechanism for the toxicity of oligomeric α-synuclein Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease Sleep drives metabolite clearance from the adult brain Dopamine-induced α-synuclein oligomers show self- and cross-propagation properties.A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy A shortened Barnes maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse model of Alzheimer's disease.What we can learn from animal models about cerebral multi-morbidity.Alpha-synuclein levels in blood plasma decline with healthy aging.Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.Genetic Association between Presenilin 2 Polymorphisms and Alzheimer's Disease and Dementia of Lewy Body Type in a Japanese Population.α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer What can biomarkers tell us about cognition in Parkinson's disease?Mini review: linkage between α-Synuclein protein and cognition.The cellular prion protein (PrPC) as neuronal receptor for α-synuclein.Effects of Alpha-Synuclein on Primary Spinal Cord Neurons Associated with Apoptosis and CNTF Expression.α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.Knockdown of α-synuclein in cerebral cortex improves neural behavior associated with apoptotic inhibition and neurotrophin expression in spinal cord transected rats.Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits.The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation.Wake up with a new brain!Mitochondrial Proteome Changes Correlating with β-Amyloid Accumulation.Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications.Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.Alzheimer's disease--emerging new potential therapeutic modalities.Therapeutic implications of how TNF links APOE, P-tau, α-synuclein, β-amyloid, and insulin resistance in neurodegenerative diseases

P2860

Q26773154-680E336F-71C0-4FA1-B912-18987D79541B Q26853347-31B059F4-44BD-4204-AF46-AA2C09248694 Q28080551-1D38984D-0F81-47AC-B3DB-B40C97AAB838 Q28082768-508A7ECB-A89E-45F3-9650-1CFDB7F585A5 Q28384947-67853FEB-CF7A-472E-A2C2-A342E76E86E6 Q29620065-14C4D19E-AD8F-4976-AC86-8B39D8596EE2 Q30364908-9431E9CE-4936-4D4C-9E97-125807AD301E Q30827953-2B59B095-92D1-49C0-9E0C-FB4E6E572AF8 Q33745617-5C254058-E7B9-4443-B0E8-59809B942818 Q33784044-F0FC7DE3-6396-402F-9712-1B5CD3D44B23 Q34544824-75A82AC6-61AE-40D3-AF0E-364FA6AB8CD1 Q35043942-9D25F676-207D-43EE-B29C-5CC8A4168F63 Q35215656-7A0517DD-3C81-40EB-B6B2-0762D718D5A5 Q35284843-83E7C645-F7D3-45E2-97B9-48D756B200B7 Q36245278-4799821D-91D8-4BD0-A417-70AA58E6148C Q36597843-509C53B2-3387-46D2-BA07-89C9C22D6F41 Q36600160-9C44A2F3-E5D8-472A-805C-9B442BFC44B5 Q36766239-483469B9-1E3C-42F9-BE0C-37467FDB912C Q37086400-876458C0-8F32-4BB0-A3B5-892E4F8BEF90 Q37127867-005985D0-1861-457B-9F58-E67B9F5F6ED0 Q37266166-6EA384C6-B436-4379-9E15-2EC902E0FA56 Q37554972-F70BD47A-9D66-4C52-BA56-35BCCC160D01 Q37693367-507C1104-5D2D-4549-90CE-634FBF7D8FC9 Q38206497-A888F797-8850-46AA-B021-83C419350228 Q38401326-C9980492-64C3-4085-8785-CA76D7BEADA7 Q38651790-6AFCB026-B1E8-4918-A7F5-0B073D1E04AB Q38825717-74EF3464-6B76-4F67-93A8-7898DFBE9FDD Q38831103-B5413627-0CD3-4380-A633-F0DCB02D987B Q38914810-DEAAD045-C562-42F3-9B8E-DBC7FA95F544 Q46362244-5075DF34-D185-44DC-BC6B-70B53DB99D22 Q46368794-D3C6DAA7-ED45-4ECF-A27E-8B5DAA7C50EE Q48133287-C52B7C3D-8284-4D9D-B3BC-F851B727186B Q48881691-CCAEFB42-E2DF-4CA4-BDE2-2C55E03DEBC0 Q50023771-63C68361-01EE-4FC0-B987-90A8D905C54F Q50525085-474C5AEE-C7D6-4940-A977-99AB5B4017F3 Q53444171-20DA29BC-F5BC-441E-A11F-7C03B6DC4705 Q56344227-005B2E01-0D7C-4CBA-931E-CA8284E21965

P2860

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

http://www.wikidata.org/entity/Q36182604

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@ast

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@en

type

label

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@ast

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@en

prefLabel

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@ast

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@en

P1433

Q36182604-7A2B2D73-9AA3-4569-9BAB-8D037023D065

P1476

Q36182604-BD2AE393-81B8-47D7-8261-33E81BF9649D

P2093

Q36182604-4658D280-1A39-4290-A58A-68F476386C18

Q36182604-705A4C5A-E0EE-4C84-958B-46D825E3F587

Q36182604-77EDEA50-EDE2-451B-94AC-08A5CEAD2528

Q36182604-7831B906-9087-4951-88C8-2706B1BF2F35

Q36182604-D8B614B1-9668-4C9F-B626-F07C6AA208B4

Q36182604-FABCBA04-0F5C-4708-B4E2-3388F1AE4C28

P2860

Q36182604-02441D28-075B-457E-8DA6-129396FA12EB

Q36182604-072A1444-8152-4735-8C24-F3AF44D769A1

Q36182604-08D8891F-BC65-426A-9349-22AD344DA514

Q36182604-08E28FE1-7A0D-4D95-9AF5-A0511E438FF3

Q36182604-10DD51C9-C327-4FFF-B6FA-DCEA60524A9F

Q36182604-124B184B-3A02-457D-ACEC-039624A9E87D

Q36182604-140056F9-250D-4021-9D5B-822E438C964F

Q36182604-1A2FBFBA-9B3B-4B23-9D32-04F85A5F5ED6

Q36182604-1AC1B0E2-2FF0-4481-91F6-58959E3F90F2

Q36182604-2013E24B-066E-41CA-94EA-9B2E02A83D47

P304

Q36182604-F1C7A897-00F5-48A1-A4E4-1D88AAE89947

P31

Q36182604-0A7DB1AE-221B-4CA5-A628-31AF0575CA5F

P356

Q36182604-B6D2FC9A-103A-42AC-93E5-BE49F1127F08

P407

Q36182604-B8E0B556-6287-4B87-A021-24B840221F39

P433

Q36182604-48352695-42EA-4F4C-90FC-2346049D35B4

P478

Q36182604-BFE7172A-7043-4F4D-AD52-52AB5BCC7D36

P50

Q36182604-C5283F55-7029-4F8B-A1E6-D88BA10DE0A4

P577

Q36182604-A6E41050-AD5F-42AE-9144-0015A487A95F

P698

Q36182604-4C105A70-9BDB-48E8-8535-C9B438362DF3

P921

Q36182604-9DF30536-CD84-4B6C-A16B-D0D01325109A

Q36182604-D2584B45-219E-4A6C-96E4-84B199098740

Q36182604-EB4FA535-E44A-4874-9F0D-AEA5D558A6BF

P932

Q36182604-2A61ED5B-919A-4C9A-8E3A-F795912534A1

P356

JNEUROSCI.0581-12.2012

P1433

Journal of Neuroscience

P1476

Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology.

@en

P2093

Julie A Schneider

http://www.w3.org/2001/XMLSchema#string

Mathew A Sherman

http://www.w3.org/2001/XMLSchema#string

Megan E Larson

http://www.w3.org/2001/XMLSchema#string

Michael Kuskowski

http://www.w3.org/2001/XMLSchema#string

Susan Greimel

http://www.w3.org/2001/XMLSchema#string

Sylvain E Lesné

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

Neuropathology in mice expressing mouse alpha-synuclein

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Assessment of α-synuclein secretion in mouse and human brain parenchyma

Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form

A specific amyloid-beta protein assembly in the brain impairs memory

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

P304

10253-10266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.0581-12.2012

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

David A Bennett

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22836259

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

pathophysiology

P932

3425439

http://www.w3.org/2001/XMLSchema#string